Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01918644 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01918644 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 21 participants.
The verdict
NCT01918644, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with capecitabine before surgery in treating patients with pancreatic cancer that can be removed by surgery. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving stereotactic body radiation therapy and capecitabine before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- OTHER laboratory biomarker analysis
- RADIATION stereotactic body radiation therapy
- PROCEDURE therapeutic conventional surgery
- DRUG capecitabine
- PROCEDURE magnetic resonance imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-04-08 |
| Est. Completion | 2022-04-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01918644
The ClinicalTrials.gov registry entry for NCT01918644 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01918644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01918644 about?
NCT01918644 is a clinical study titled "Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer". This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with capecitabine before surgery in treating patients with pancreatic cancer that can be removed by surgery. Stereotactic body radiation therapy may be able to send x-rays directly to...
What is the current status of trial NCT01918644?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2014-04-08. Estimated completion is 2022-04-26.
What interventions are being tested in trial NCT01918644?
The interventions under investigation include: laboratory biomarker analysis (OTHER), stereotactic body radiation therapy (RADIATION), therapeutic conventional surgery (PROCEDURE), capecitabine (DRUG), magnetic resonance imaging (PROCEDURE).
Who is sponsoring clinical trial NCT01918644?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.